AU2000277238A1 - Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy - Google Patents
Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapyInfo
- Publication number
- AU2000277238A1 AU2000277238A1 AU2000277238A AU7723800A AU2000277238A1 AU 2000277238 A1 AU2000277238 A1 AU 2000277238A1 AU 2000277238 A AU2000277238 A AU 2000277238A AU 7723800 A AU7723800 A AU 7723800A AU 2000277238 A1 AU2000277238 A1 AU 2000277238A1
- Authority
- AU
- Australia
- Prior art keywords
- gnrh
- analogs
- mammalian
- tumor cell
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000033228 biological regulation Effects 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
- 230000004565 tumor cell growth Effects 0.000 title 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 4
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 abstract 2
- 102000008238 LHRH Receptors Human genes 0.000 abstract 2
- 108010021290 LHRH Receptors Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- NMJREATYWWNIKX-XJIZABAQSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 NMJREATYWWNIKX-XJIZABAQSA-N 0.000 abstract 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 abstract 1
- 241000252203 Clupea harengus Species 0.000 abstract 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 abstract 1
- 229930028154 D-arginine Natural products 0.000 abstract 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 abstract 1
- 229930182819 D-leucine Natural products 0.000 abstract 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 abstract 1
- 102000005593 Endopeptidases Human genes 0.000 abstract 1
- 108010059378 Endopeptidases Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 108700015863 His(5)-Trp(7)-Tyr(8)- LHRH Proteins 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 1
- 150000001408 amides Chemical group 0.000 abstract 1
- 230000002001 anti-metastasis Effects 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000001640 apoptogenic effect Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 229940066758 endopeptidases Drugs 0.000 abstract 1
- 229940088598 enzyme Drugs 0.000 abstract 1
- 235000019514 herring Nutrition 0.000 abstract 1
- 235000019833 protease Nutrition 0.000 abstract 1
- 230000000541 pulsatile effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrotherapy Devices (AREA)
Abstract
Specially designed non-mammalian GnRH analogs resistant to degradation by the tumor tissue enzymes, post-proline peptidases as well as endopeptidases, are disclosed. The GnRH analogs are further defined as analogs of chicken II GnRH, salmon GnRH, or herring GnRH, but can include any non-mammalian GnRH analog with similar amino acid structure. These non-mammalian analogs incorporate D-arginine, D-leucine, D-tBu-Serine or D-Trp or other similar amino acids at position 6 and ethylamide or aza-Gly-amide or similar amides at position 10. These analogs demonstrate preferential binding to tumor cell GnRH receptors that is greater relative to the binding of the mammalian analogs to the tumor cell GnRH receptor. These non-mammalian GnRH analogs may be used in pharmaceutical preparations, and it specifically in various treatments as an anti-tumor, anti-proliferation, anti-metastatic and/or an apoptotic agent. The non-mammalian GnRH analogs are also provided in pharmaceutical preparations that may be used clinically for tumor regression when used in very low doses and administered in pulsatile fashion.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09540685 | 2000-03-31 | ||
| US09/540,685 US7834141B1 (en) | 2000-03-31 | 2000-03-31 | Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy |
| PCT/US2000/026575 WO2001074377A1 (en) | 2000-03-31 | 2000-09-26 | Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2000277238A1 true AU2000277238A1 (en) | 2001-10-15 |
Family
ID=24156514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2000277238A Abandoned AU2000277238A1 (en) | 2000-03-31 | 2000-09-26 | Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7834141B1 (en) |
| EP (1) | EP1272206B1 (en) |
| JP (1) | JP2004512011A (en) |
| AT (1) | ATE494902T1 (en) |
| AU (1) | AU2000277238A1 (en) |
| DE (1) | DE60045524D1 (en) |
| WO (1) | WO2001074377A1 (en) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635739B2 (en) * | 1999-10-15 | 2003-10-21 | Theresa Siler-Khodr | Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy |
| US20040152639A1 (en) * | 2001-08-28 | 2004-08-05 | Siler-Khodr Theresa M. | Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy |
| JP4162682B2 (en) | 2002-07-22 | 2008-10-08 | アーダナ バイオサイエンス リミテッド | Screening method and antitumor drug candidate obtained therefrom |
| RU2005111253A (en) * | 2002-09-18 | 2005-11-20 | Сантр Оспиталье Де Л` Юниверсите Де Монреаль (Схюм) (Ca) | GHRH ANALOGUES |
| AU2003292696A1 (en) | 2002-12-26 | 2004-08-10 | Takeda Pharmaceutical Company Limited | Metastin derivative and use thereof |
| WO2004080479A1 (en) | 2003-03-12 | 2004-09-23 | Takeda Pharmaceutical Company Limited | Gonadal function improving agents |
| US20050043245A1 (en) * | 2003-08-11 | 2005-02-24 | Siler -Khodr Theresa M. | Non-mammalian GnRH analogs and uses thereof in the immune system |
| US20050054576A1 (en) * | 2003-08-12 | 2005-03-10 | Siler-Khodr Theresa M. | Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy |
| WO2005018660A1 (en) * | 2003-08-12 | 2005-03-03 | Siler-Khodr Theresa M | Non-mammalian gnrh analogs and uses thereof in regulation of fertility and pregnancy |
| CN101845091A (en) | 2004-06-25 | 2010-09-29 | 武田药品工业株式会社 | Transferin derivatives and uses thereof |
| CA2614532A1 (en) | 2005-07-26 | 2007-02-01 | Georg-August-Universitaet Goettingen | Method for induction and enhancement of apoptosis in tumor cells |
| US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| TWI386417B (en) | 2005-12-22 | 2013-02-21 | Takeda Pharmaceutical | Metastin derivatives and use thereof |
| GB0616111D0 (en) | 2006-06-16 | 2006-09-20 | Ardana Bioscience Ltd | Agents, methods and uses |
| JO3048B1 (en) | 2006-10-25 | 2016-09-05 | Takeda Pharmaceuticals Co | Metastin Derivatives And Use Thereof |
| ES2469802T3 (en) * | 2008-10-20 | 2014-06-20 | Valipharma | Methods and uses involving genetic aberrations of NAV 3 and aberrant expression of multiple genes |
| US20120045393A1 (en) * | 2009-03-17 | 2012-02-23 | Linder Karen E | Lhrh-ii peptide analogs |
| US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
| US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US9849160B2 (en) * | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
| US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
| US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| WO2018134373A1 (en) * | 2017-01-20 | 2018-07-26 | Immune System Regulation Holding Ab | Novel compounds (immunorhelins- intracellular infections) |
| US11304990B2 (en) | 2017-01-20 | 2022-04-19 | ISR Immune System Regulation Holding AB (publ) | Use of known compounds—intracellular infections |
| AU2018209236B2 (en) * | 2017-01-20 | 2023-02-02 | ISR Immune System Regulation Holding AB (publ) | Novel compounds (immunorhelins) |
| CN110381978A (en) | 2017-02-22 | 2019-10-25 | 免疫系统调节控股有限公司 | Gonadotropin-releasing hormone (GRH) is used as the purposes of skeptophylaxis therapeutic agent |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2029018A1 (en) * | 1989-11-01 | 1991-05-02 | Robert P. Millar | Analogues of gonadotropin releasing hormone |
| US5760000A (en) * | 1994-05-13 | 1998-06-02 | University Technologies International,Inc. | Inhibition of liver cancer by the use of GnRH and GnRH analogs |
| US6323179B1 (en) * | 1999-10-15 | 2001-11-27 | Theresa Siler-Khodr | Chicken GNRH analogs and uses thereof in regulation of fertility and pregnancy |
| US6635739B2 (en) * | 1999-10-15 | 2003-10-21 | Theresa Siler-Khodr | Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy |
-
2000
- 2000-03-31 US US09/540,685 patent/US7834141B1/en not_active Expired - Fee Related
- 2000-09-26 DE DE60045524T patent/DE60045524D1/en not_active Expired - Lifetime
- 2000-09-26 JP JP2001572119A patent/JP2004512011A/en active Pending
- 2000-09-26 EP EP00966971A patent/EP1272206B1/en not_active Expired - Lifetime
- 2000-09-26 AU AU2000277238A patent/AU2000277238A1/en not_active Abandoned
- 2000-09-26 WO PCT/US2000/026575 patent/WO2001074377A1/en not_active Ceased
- 2000-09-26 AT AT00966971T patent/ATE494902T1/en not_active IP Right Cessation
-
2003
- 2003-09-03 US US10/654,192 patent/US20040097412A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004512011A (en) | 2004-04-22 |
| ATE494902T1 (en) | 2011-01-15 |
| US7834141B1 (en) | 2010-11-16 |
| WO2001074377A1 (en) | 2001-10-11 |
| EP1272206B1 (en) | 2011-01-12 |
| DE60045524D1 (en) | 2011-02-24 |
| US20040097412A1 (en) | 2004-05-20 |
| EP1272206A1 (en) | 2003-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2000277238A1 (en) | Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy | |
| EP1626055A3 (en) | Non-mammalian GnRH analogs and uses thereof in the regulation of the immune system | |
| PL370823A1 (en) | Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors | |
| CA2203694A1 (en) | Cancer inhibitory peptides | |
| GEP20043354B (en) | Therapeutic Formulation for Administering Tolterodine with Controlled Release | |
| ATE204881T1 (en) | CHIMERIC LIPID BODY PRO-GRF ANALOGUE WITH INCREASED BIOLOGICAL POTENCY | |
| MY103746A (en) | Improvements in or relating to somatostatins | |
| WO2001030802A3 (en) | Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies | |
| EP0911331A3 (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
| TR200101633T2 (en) | Pharmaceutical composition | |
| MY139203A (en) | Pharmaceutical composition | |
| IL137820A0 (en) | Pharmaceutical composition comprising an analgesic peptide | |
| ATE546461T1 (en) | GNRH NON-MAMMAL ANALOGUE AND USE FOR REGULATION OF FERTILITY AND PREGNANCY | |
| WO2005018657A3 (en) | NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY | |
| BR0213823A (en) | Method of Administration of a Thymosin Alpha Peptide 1 | |
| MY136546A (en) | A pharmaceutical component based on human parathyroid harmone and a pharmaceutical composition for intranasal administration comprising the component | |
| EP1586581A3 (en) | Non-Mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy | |
| EA200301295A1 (en) | POLYPEPTIDE, ITS CONJUGATE WITH DOXORUBICIN AND PHARMACEUTICAL COMPOSITION ON ITS BASIS | |
| WO2005019457A3 (en) | NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY | |
| PL357999A1 (en) | Lhrh-antagonists, production and use thereof as medicament | |
| CA2530611A1 (en) | Biologically active peptide comprising tyrosyl-seryl-valine (ysv) | |
| GB9914480D0 (en) | Use of peptides | |
| WO2003016331A3 (en) | Non-mammalian gnrh analogs and uses thereof in regulation of fertility and pregnancy | |
| WO2005019448A3 (en) | NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY | |
| EP0670165A2 (en) | Use of seminal ribonuclease as antimetastatic compound |